SLXN•benzinga•
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer
Summary
Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS mutation profiles in preclinical studies.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 5, 2025 by benzinga